Search Results - Mark Levis
- Showing 1 - 10 results of 10
-
1
-
2
The current therapeutic landscape of FLT3 inhibitors by Mark Levis
Published in Blood Advances (2017-10-01)Get full text
Article -
3
Inhibition of c-Kit by tyrosine kinase inhibitors by Allison Galanis, Mark Levis
Published in Haematologica (2015-03-01)Get full text
Article -
4
Potential targeting of <i>FLT3</i> acute myeloid leukemia by Alexander J. Ambinder, Mark Levis
Published in Haematologica (2020-07-01)Get full text
Article -
5
A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia by Lauren Lee, Yoshiyuki Hizukuri, Paul Severson, Benjamin Powell, Chao Zhang, Yan Ma, Maiko Narahara, Hiroyuki Sumi, Daniela Hernandez, Trivikram Rajkhowa, Gideon Bollag, Mark Levis
Published in Haematologica (2021-01-01)Get full text
Article -
6
V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML by Vinod A. Pullarkat, Mark Levis, James McCloskey, Gabriel N. Mannis, Stephen A. Strickland, Amir T. Fathi, Tara L. Lin, Vijaya R. Bhatt, Thuva Vanniyasingam, Divya Chakravarthy, Yana Lutska, Stefan Faderl, Ronald S. Cheung, Harry P. Erba
Published in Blood Neoplasia (2025-11-01)Get full text
Article -
7
Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia by Paul Milne, Charlotte Wilhelm-Benartzi, Michael R. Grunwald, Venetia Bigley, Richard Dillon, Sylvie D. Freeman, Kathleen Gallagher, Amy Publicover, Sarah Pagan, Helen Marr, Gail L. Jones, Anne M. Dickinson, Angela Grech, Alan K. Burnett, Nigel H. Russell, Mark Levis, Steven Knapper, Matthew Collin
Published in Blood Advances (2019-10-01)Get full text
Article -
8
A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia by Keith W. Pratz, Jason Kaplan, Moshe Levy, Dale Bixby, Patrick W. Burke, Harry Erba, Trisha M. Wise-Draper, Gail J. Roboz, Nikolaos Papadantonakis, Trivikram Rajkhowa, Daniela Hernandez, Iwona Dobler, Richard C. Gregory, Cheryl Li, Shining Wang, Kate Stumpo, Karuppiah Kannan, Harry Miao, Mark Levis
Published in Haematologica (2022-10-01)Get full text
Article -
9
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome by Mahesh Swaminathan, Hagop M Kantarjian, Mark Levis, Veronica Guerra, Gautam Borthakur, Yesid Alvarado, Courtney D DiNardo, Tapan Kadia, Guillermo Garcia-Manero, Maro Ohanian, Naval Daver, Marina Konopleva, Naveen Pemmaraju, Alessandra Ferrajoli, Michael Andreeff, Nitin Jain, Zeev Estrov, Elias J Jabbour, William G Wierda, Sherry Pierce, Maria Rhona Pinsoy, Lianchun Xiao, Farhad Ravandi, Jorge E Cortes
Published in Haematologica (2021-04-01)Get full text
Article -
10
Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4 by Sabine Kayser, David Martínez-Cuadrón, Maher Hanoun, Friedrich Stölzel, Cristina Gil, H. Christian Reinhardt, Eliana Aguiar, Kerstin Schäfer-Eckart, Juan Miguel Bergua Burgues, Björn Steffen, Teresa Bernal, Stefan W. Krause, Rosalía Riaza, Christoph Schliemann, Jose Cervera, Martin Kaufmann, Laura Torres-Miñana, Mathias Hänel, Evelyn Acuña-Cruz, Edgar Jost, Jesus Lorenzo Algarra, Martina Crysandt, Lars Fransecky, Javier Cornago-Navascues, Sabrina Kraus, Joaquin Martinez-Lopez, Hermann Einsele, Dirk Niemann, Andreas Neubauer, Ruth Seggewiß-Bernhardt, Sebastian Scholl, Stefan A. Klein, Christoph Schmid, Markus Schaich, Martin Schmidt-Hieber, Sven Zukunft, Anthony D. Ho, Uwe Platzbecker, Claudia D. Baldus, Carsten Müller-Tidow, Christian Thiede, Martin Bornhäuser, Hubert Serve, Mark Levis, Pau Montesinos, Christoph Röllig, Richard F. Schlenk
Published in Haematologica (2022-06-01)Get full text
Article